prostaglandin E2
The definitions used in this glossary of terminology either have been provided by the authors of the articles, or have been extracted wholly or in part, or paraphrased from the following sources: The American Medical Association Encyclopedia of Medicine, Charles B. Clayman, MD, Medical Editor, Random House, New York, 1989; Biotechnology from A to Z, 2d Edition, William Bains, Oxford University Press, New York, New York, 2002; A Dictionary of Genetics, 6th Edition, Robert C. King and William D. Stansfield, Oxford University Press, New York, New York, 2002; Dorland's Illustrated Medical Dictionary, 29th and 30th Editions, W. B. Saunders Company, Philadelphia, 2000, 2003; Genes VII, Benjamin Lewin, Oxford University Press, New York, New York, 2000; The Gale Encyclopedia of Genetic Disorders, Volumes I and II, Stacey L. Blachford, Ed., Thomson Learning, New York, New York, 2002; The Merriam-Webster Dictionary, Merriam-Webster, Inc., Springfield, Massachusetts, 1997; Molecular Biology of the Cell, 3rd Edition, Bruce Alberts, et al., Garland Publishing, 1994; The Random House Dictionary of the English Language, Unabridged Edition, 1966; Webster's Ninth New Collegiate Dictionary, 1991.
DEFINITION:
- prostaglandin E2
-
(PGE2), an important prostaglandin produced in the renal medulla, gastrointestinal mucosa, and other tissues; it causes renal vasodilation and inhibition of renal tubular sodium resorption, inhibition of gastric secretion, and either contraction or relaxation of smooth muscle (depending on the tissue). It is also released by macrophages and modulates several inflammatory responses; it increases vascular permeability, increases pain sensitivity, is pyrogenic, and suppresses lymphocyte transformation, release of mediators from mast cells, and cell-mediated cytotoxicity. PGE2 produced by some tumors causes hypercalcemia by stimulation of bone resorption by osteoclasts. When used pharmaceutically its nonproprietary name is dinoprostone .
Used in 2 Article bodies
Used in 2 Article bodies